Enteric-coated mycophenolate sodium

Expert Opinion on Drug Safety

Volumn 9, Issue 6, 2010, Pages 981-994

  Budde, Klemens ^a   Drr, Michael ^a   Liefeldt, Lutz ^a   Neumayer, Hans Hellmut ^a   Glander, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

EC MPS; Enteric coated mycophenolate sodium; Gastrointestinal; Mycophenolic acid; Myfortic; Transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; TACROLIMUS;

ABDOMINAL PAIN; ANEMIA; AREA UNDER THE CURVE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENTERIC COATED TABLET; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MAXIMUM ALLOWABLE CONCENTRATION; POLYOMAVIRUS INFECTION; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; WOUND INFECTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 77958035150     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.513379     Document Type: Review

References (97)

1. Tedesco-Silva H, Bastien MC, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005;37:852-855
2. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19:199-206
3. Budde K, Glander P, Kramer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007;83:417-424 (Pubitemid 46667845)
4. Salvadori M, Holzer H, de Mattos A, et al.; on behalf of the ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4:231-236
5. Budde K, Curtis J, Knoll G, et al.; on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004;4:237-243
6. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007;84:1443-1451
7. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006;81:1290-1297
8. Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008;40:2262-2267
9. Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int 2009;22:821-830
10. Robaeys G, Cassiman D, Verslype C, et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc 2009;41:610-613
11. Miras M, Carballo F, Egea J, et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 2007;39:2314-2317
12. Dumortier J, Gagnieu MC, Salandre J, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006;12:1342-1346
13. Kobashigawa JA, Renlund DG, Gerosa G, et al.; ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006;25:935-941
14. Lehmkuhl H, Hummel M, Kobashigawa J, et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008;40:953-955
15. Melle TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000;47:215-245
16. Van Gelder T, Klupp J, Kavanau K, Morris RE. Novel mechanisms of action of mycophenolic acid (MPA): inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). Transplantation 2000;6:S393
17. Barten MJ, van Gelder T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002;2:719-732
18. Barten MJ, van Gelder T, Gummert JF, et al. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol 2002;10:1-14
19. Kamar N, Glander P, Nolting J, et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin J Am Soc Nephrol 2009;4:936-942
20. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006;82:1413-1418
21. Reyes H, Hernandez AM, Valverde S, et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplant 2010. [Epub ahead of print]
22. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007;7:888-898 (Pubitemid 46481185)
23. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58
24. Kuypers DR, Meur YL, Cantarovich M, et al.; Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341-358
25. De Winter BC, van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008;47:827-838
26. Tedesco-Silva H, Felipe CR, Park SI, et al. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Clin Transplant 2009. [Epub ahead of print]
27. Sanchez-Fructuoso A, Calvo N, Moreno MA, et al. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Transplant Proc 2007;39:2194-2196
28. Budde K, Tedesco-Silva H, Pestana JM, et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 2007;29:381-384
29. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17:871-880
30. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009;31:416-435
31. Grinyo JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2008;24:2269-2276
32. Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005;19:551-558
33. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008;30:46-51
34. Kofler S, Deutsch M-A, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant 2009;28:605-611
35. Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009;49:1196-1201
36. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-678
37. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266
38. Granger DK, for the ERL B 301 Renal Transplant Study Group. ERL B 302 Renal Transplant Study Group. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001;33:3241-3244
39. Salvadori M, Bertoni E, Budde K, et al. EC-MPS is associated with superior efficacy outcomes compared with MMF in de novo renal transplant recipients: a pooled analysis. Transplant Proc 2010;42:1325-1328
40. Sommerer C, Muller-Krebs S, Schaier M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010;69:346-357
41. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86:1043-1051
42. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009;9:1607-1619
43. Barraclough KA, Isbel NM, Staatz CE. Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials. Transplantation 2010;90:44-51
44. de Winter BC, van Gelder T, Mathot RA, et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009;31:585-591
45. Niaudet P, Charbit M, Loirat C, et al. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. Pediatr Nephrol 2009;24:395-402
46. Legendre C, Cohen D, Zeier M, et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc 2007;39:1386-1391
47. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008;86:67-74
48. Friman S, Arns W, Banas B, et al. Sotrastaurin and mycophenolic acid in de novo renal transplant patients: efficacy and safety of a CNI-free regimen [abstract O-29]. Presented at 14th ESOT Congress 2009; 30th August - 2nd September, Paris
49. Vincenti F, Friman S, Scheuermann E, et al.; DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-1514
50. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010;10:571-581
51. Andres A, Bloom R, Bunnapradist S, et al.; ERL A2409 Study Group. Randomized, multicenter study on the safety and efficacy of enteric-coated mycophenolate sodium combined with basiliximab and low- or standard dose of tacrolimus in de novo renal transplant patients. Transpl Int 2007;20(S2):217
52. Kamar N, Mariat C, Albano L, et al. Improvement in renal function following conversion from low-dose mycophenolate acid to higher-dose enteric-coated mycophenolate sodium (EC-MPS) with concomitant tacrolimus reduction in maintenance kidney transplant recipients [abstract O-295]. Transpl Int 2009;22(Suppl 2):78
53. Hart M, Chan L, Andres A, et al. Renal function with enteric-coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6-month comparative study in de novo renal transplant recipients [abstract 1526]. Am J Transplant 2008;8(Suppl 2):583
54. Sollinger HW, Sundberg AK, Leverson G, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010;89:46-51
55. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009;88:514-520
56. Irish W, Arcona S, Gifford RJ, et al. Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network Database. Transplantation 2010;90:23-30
57. Glander P, Sommerer C, Arns W, et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010;5:503-511
58. Sommerer C, Budde K, Zeier M, et al. An intensified dosing of enteric-coated mycophenolate sodium in renal transplant patients results in improved efficacy without compromising safety: 1 year follow-up results [abstract 1235]. Am J Transplant 2010;10(S4):394
59. Budde K, Tedesco-Silva H, Arns W, et al. Improved rejection prophylaxis from an initial intensified dosing regimen of enteric-coated mycophenolate sodium (EC-MPS) in de novo renal transplant recipients [abstract 1234]. Am J Transplant 2010;10(S4):393
60. Kuypers D, Budde K, Arns W. Initially intensified dosing of enteric-coated mycophenolate sodium (EC-MPS) has comparable patient reported outcomes to standard dosing in de novo renal transplant recipients [abstract 1242]. Am J Transplant 2010;10(S4):396
61. Touchard G, Mourad G, Lebranchu Y, et al. Multicenter, randomized, comparative, open-label study to evaluate efficacy and safety a combination of anti-IL2R, intensified dose of enteric-coated mycophenolate sodium (EC-MPS) for 6 weeks, ciclosporine micro-emulsion (CSA-ME), with or without steroids, in adult kidney de novo transplant recipients (TXR) [abstract 1679]. Am J Transplant 2010;10(S4):515
62. Weimert N, Alloway R, Vinks A, et al. A 12 month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic- in combination with tacrolimus and thymoglobulin in early corticosteroid withdrawal [abstract 102]. Transplantation 2008;86(S):36
63. Pietruck F, Klempnauer J, Arns W, et al. Efficacy and safety of everolimus (RAD)/enteric-coated mycophenolate sodium (EC-MPS) after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final results of the ZEUS trial [abstract 1093]. Am J Transplant 2009;9:259
64. Budde K, Arns W, Sommerer C, et al. Improved renal function of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow-up of the ZEUS Trial [abstract 1638]. Am J Transplant 2010;10(S4):503
65. Budde K, Zeier M, Haller H, et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract 1639]. Am J Transplant 2010;10(S4):504
66. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006;66:103-111 (Pubitemid 44219436)
67. Pietruck F, Abbud-Filho M, Vathsala A, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc 2007;39:103-108
68. Bilodeau JF, Montambault P, Wolff JL, et al. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2009;41:3683-3689
69. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386
70. Tierce J, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005;19:779-784
71. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006;82:102-107
72. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004;17:609-616
73. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003;17:200-205
74. Hardinger KL, Hebbar S, Bloomer T, Murillo D. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 2008;22:555-561
75. Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Quality of life and tolerability of enteric-coated mycophenolate sodium (EC-MPS) in renal transplant recipients with gastrointestinal tract complaints to mycophenolate mofetil (MMF): a multicenter, randomized, open-label, controlled trial. Am J Transplant 2009;9(Suppl 3):abstract 749
76. Massari P, Duro-Garcia V, Giron F, et al.; myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005;37:916-919
77. Sabbatini M, Capone D, Gallo R, et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009;23:617-624
78. Meneses Rde P, Kotsifas CH. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transplant 2009;13:188-193
79. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improved graft survival in renal transplant recipients when compared to azathioprine: a systematic review. Transplantation 2009;87:785-794
80. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004;36:2068-2070 (Pubitemid 39424328)
81. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532-1540 (Pubitemid 39552941)
82. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005;80:303-309
83. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004;77:244-251
84. Tedesco-Silva H, Kim YS, Lackova E, et al. Everolimus with reduced-dose cyclosporine: results from a randomized study in 833 de-novo renal-transplant recipients. Transpl Int 2009;22(S2):186
85. Bertoni E, Larti A, Farsetti S, et al. Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M). Transpl Int 2009;22(S2):91
86. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006;6:1617-1623
87. Langone AJ, Chan L, Wiland A, et al. Conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in renal transplant recipients with diabetes mellitus (DM). J Am Soc Nephrol 2009;20:abstract TH-PO1014
88. Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008;12:640-642
89. Kahan BD, Podbielski J, Childs B. The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen. Transplant Proc 2008;40:1429-1434
90. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383
91. Cofan F, Rosich E, Arias M, et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2007;39:2179-2181
92. Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 2005;9:780-787
93. Ferraris JR, Tambutti ML, Prigoshin N, et al. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: higher mycophenolic acid predose level but no changes in the immune biomarkers. Pediatr Transplant 2009;13:731-736
94. Nure E, Magalini SC, Frongillo F, et al. Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients. Transplant Proc 2009;41:1290-1292
95. Barrera-Pulido L, Alamo-Martinez JM, Marin-Gomez LM, et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. Transplant Proc 2009;41:2192-2194
96. Sogovia J, Gerosa G, Almenar L, et al. Impact of dose reductions on efficacy outcomes in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation. Clin Transplant 2008;22:809-814
97. Rangel EB, Melaragno CS, Sa JR, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation. Transplant Proc 2009;41:4265-4269